Immuno-Oncology is a rapidly evolving area in oncology using the body’s own immune system to kill cancer cells. Recent innovation, clinical proof-of-concept and regulatory approvals indicate the cancer immunotherapy is finally here to stay and opens a new era in the treatment of cancer.
The “Norwegian Immuno-Oncology Consortium” kicked off in March 2013. Oslo Cancer Cluster initiated the consortium together with Bristol-Myers Squibb, a leading global player in immuno-oncology. The Consortium aims to further advance education, partnerships and innovation within this highly specialized and disruptive field.
Core expertise within immuno-oncology exists along the value chain and across the member groups of Oslo Cancer Cluster and makes us well positioned to contribute to advancements in the field to deliver innovations for cancer patients.